COVID-19 vaccination: challenges in the pediatric population

Alice Nicoleta Azoicai1, Ingrith Miron1, Ancuta Lupu1

  • 1Pediatrics, "Grigore T. Popa" University of Medicine and Pharmacy, Iasi, Romania.

Frontiers in Public Health
|February 13, 2025
PubMed

Insights

COVID-19 vaccines demonstrate effectiveness and safety in children aged 0-18 years, showing sustained immune responses. Long-term monitoring is crucial for future vaccine development against pandemics.

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • The COVID-19 pandemic, caused by SARS-CoV-2, necessitated rapid vaccine development.
  • Vaccination is a key strategy for individual and population protection against infectious diseases.
  • Pediatric populations were included in vaccination efforts, requiring specific safety and efficacy evaluations.

Purpose of the Study:

  • To review and summarize the existing literature on COVID-19 vaccine efficacy and safety in children aged 0 to 18 years.
  • To assess the immune response and tolerability of COVID-19 vaccines in pediatric populations.
  • To inform public health strategies regarding pediatric immunization during the pandemic.

Main Methods:

  • Systematic review of published clinical trials and studies on COVID-19 vaccines in children.
  • Analysis of data on immune response, vaccine effectiveness, and adverse events.
  • Evaluation of vaccination schedules and their impact on pediatric populations.

Main Results:

  • Most studies report a sustained immune response in children and adolescents following COVID-19 vaccination.
  • Vaccination schedules were generally found to be effective and safe across various pediatric age groups.
  • Evidence suggests a favorable benefit-risk profile for COVID-19 vaccination in children.

Conclusions:

  • COVID-19 vaccination is effective and safe for the pediatric population (0-18 years).
  • Continued monitoring for long-term side effects is essential for refining pediatric vaccination strategies.
  • Further research on population-level efficacy and long-term outcomes will guide future pandemic preparedness.